Genentech/Xoma Xanelim BLA delay
Executive Summary
Genentech/Xoma's Xanelim (efalizumab) BLA filing will be delayed beyond summer 2002, companies announce April 5. A pharmacokinetic study comparing Genentech-produced to Xoma-produced drug did not achieve statistical definition of comparability. Genentech had projected a summer 2002 BLA filing for the psoriasis therapy (1"The Pink Sheet" Jan. 21, p. 32)...
You may also be interested in...
Genentech efalizumab is Raptiva
Genentech/Xoma change name of psoriasis agent Xanelim to Raptiva in order to "limit potential confusion" with Idec's non-Hodgkin's lymphoma agent Zevalin. The efalizumab BLA filing was delayed after a pharmacokinetic study comparing Xoma-produced study drug to Genentech-produced commercial drug was not found to be comparable (1"The Pink Sheet" April 8, In Brief). Genentech hopes to file the BLA before the end of 2002...
Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says
Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.